Rosen LS - Search Results

1

Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.

Rosen LS. Rosen LS. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):103-9. Oncology (Williston Park). 1998. PMID: 9726101 Review.

2

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Saltz LB, et al. Among authors: rosen ls. N Engl J Med. 2000 Sep 28;343(13):905-14. doi: 10.1056/NEJM200009283431302. N Engl J Med. 2000. PMID: 11006366 Clinical Trial.

3

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Rosen LS, et al. Cancer J. 2001 Sep-Oct;7(5):377-87. Cancer J. 2001. PMID: 11693896 Clinical Trial.

4

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.

Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS. Delioukina ML, et al. Among authors: rosen ls, rosen p. Cancer. 2002 Apr 15;94(8):2174-9. doi: 10.1002/cncr.10432. Cancer. 2002. PMID: 12001114 Clinical Trial.

5

Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.

Amado RG, Rosen LS, Hecht JR, Lin LS, Rosen PJ. Amado RG, et al. Among authors: rosen ls, rosen pj. Ann Oncol. 2002 Apr;13(4):582-8. doi: 10.1093/annonc/mdf090. Ann Oncol. 2002. PMID: 12056709 Clinical Trial.

6

Biologic approaches to the treatment of gastrointestinal malignancy.

Rosen LS. Rosen LS. Curr Opin Oncol. 2002 Jul;14(4):431-8. doi: 10.1097/00001622-200207000-00011. Curr Opin Oncol. 2002. PMID: 12130929 Review.

7

Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.

Rosen L, Harland SJ, Oosterlinck W. Rosen L, et al. Am J Clin Oncol. 2002 Dec;25(6 Suppl 1):S19-24. doi: 10.1097/00000421-200212001-00004. Am J Clin Oncol. 2002. PMID: 12562047 Review.

8

Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.

Rosen LS. Rosen LS. Semin Oncol. 2002 Dec;29(6 Suppl 21):28-32. doi: 10.1053/sonc.2002.37416. Semin Oncol. 2002. PMID: 12584692 Review.

9

Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies.

Rosen LS, Laxa B, Boulos L, Wiggins L, Keck JG, Jameson AJ, Parra R, Patel K, Brown GL. Rosen LS, et al. Clin Cancer Res. 2004 Jun 1;10(11):3689-98. doi: 10.1158/1078-0432.CCR-03-0687. Clin Cancer Res. 2004. PMID: 15173075 Clinical Trial.

10

New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.

Rosen LS. Rosen LS. Oncology (Williston Park). 2004 May;18(5 Suppl 3):26-32. Oncology (Williston Park). 2004. PMID: 15202585 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results